Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.

Aethlon Medical, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SECOND COHORT FINDINGS CONSISTENT WITH PREVIOUSLY REPORTED OBSERVATIONS; INDEPENDENT STATISTICAL ANALYSIS PLANNED FOLLOWING COMPLETION OF ALL THREE PATIENT COHORTS SAN DIEGO, JULY 13, 2026 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE-THREATENING VIRAL INFECTIONS, TODAY ANNOUNCED THAT PATIENTS IN THE SECOND COHORT OF ITS AUSTRALIAN ONCOLOGY FEASIBILITY STUDY DEMONSTRATED BIOLOGICAL CHANGES CONSISTENT WITH THOSE PREVIOUSLY OBSERVED IN THE FIRST COHORT FOLLOWING TREATMENT WITH THE INVESTIGATIONAL HEMOPURIFIER. REPLICATING THESE FINDINGS IN A SECOND GROUP OF PATIENTS STRENGTHENS THE SCIENTIFIC RATIONALE FOR THE COMPANY'S ONGOING CLINICAL PROGRAM AND SUPPORTS CONTINUED ENROLLMENT IN THE THIRD AND FINAL COHORT BEFORE AN INDEPENDENT STATISTICAL ANALYSIS IS CONDUCTED.

AETHLON MEDICAL CONTINUES TO OBSERVE DIRECTIONAL CHANGES IN SECOND COHORT OF AUSTRALIAN ONCOLOGY CLINICAL TRIAL EVALUATING HEMOPURIFIER

SAN DIEGO, JULY 6, 2026 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE-THREATENING INFECTIOUS DISEASES, TODAY ANNOUNCED THE PRICING OFITS FOLLOW-ON OFFERING OF 5,633,009 SHARES OF ITS COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) AND WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 5,633,009 SHARES OF ITS COMMON STOCK AT A COMBINED PUBLIC OFFERING PRICE OF $0.7101 PER SHARE (OR PRE-FUNDED WARRANT) AND ACCOMPANYING WARRANT, PRICED AT-THE-MARKET UNDER APPLICABLE NASDAQ RULES. THE WARRANTS WILL HAVE AN EXERCISE PRICE OF $0.7101 PER SHARE, WILL BE EXERCISABLE UPON THE DATE OF STOCKHOLDER APPROVAL, AND WILL EXPIRE ON THE FIVE-YEAR ANNIVERSARY FROM THE DATE OF STOCKHOLDER APPROVAL.

AETHLON MEDICAL ANNOUNCES PRICING OF $4.0 MILLION FOLLOW-ON OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

PEER-REVIEWED STUDY IDENTIFIES ALTERED EXTRACELLULAR VESICLES IN LONG COVID AND PROVIDES ADDITIONAL SCIENTIFIC RATIONALE FOR EVALUATING THE HEMOPURIFIER AS A POTENTIAL TREATMENT SAN DIEGO, JUNE 26, 2026 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE-THREATENING INFECTIOUS DISEASES, TODAY ANNOUNCED PUBLICATION OF NEW PEER-REVIEWED RESEARCH IN THE INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES DEMONSTRATING THAT PATIENTS WITH LONG COVID EXHIBIT SIGNIFICANTLY INCREASED LEVELS OF MANNOSYLATED EXTRACELLULAR VESICLES (EVS) THAT CAN BE CAPTURED USING THE SAME GALANTHUS NIVALIS AGGLUTININ (GNA) AFFINITY RESIN INCORPORATED INTO THE COMPANY'S HEMOPURIFIER. THE STUDY, CONDUCTED IN COLLABORATION WITH INVESTIGATORS FROM THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (UCSF), PROVIDES WHAT WE BELIEVE IS NEW EVIDENCE SUPPORTING EXTRACELLULAR VESICLES AS A POTENTIAL THERAPEUTIC TARGET IN LONG COVID AND HELPS ESTABLISH A TRANSLATIONAL FRAMEWORK FOR FUTURE STUDIES EVALUATING WHETHER THE HEMOPURIFIER CAN REMOVE DISEASE-ASSOCIATED EVS AND THEIR MOLECULAR CARGO.

AETHLON MEDICAL ANNOUNCES PUBLICATION DEMONSTRATING NOVEL LONG COVID BIOMARKER AND POTENTIAL THERAPEUTIC TARGET FOR THE HEMOPURIFIER

VANCOUVER, KELOWNA, AND DELTA, BRITISH COLUMBIA--(NEWSFILE CORP. - JUNE 26, 2026) - INVESTORIDEAS.COM, A LEADING INVESTMENT PLATFORM FOR RETAIL INVESTORS

FROM VACCINES TO THERAPEUTICS; HOW BIOTECH IS ADDRESSING THE EBOLA OUTBREAK

AUSTRALIAN ONCOLOGY STUDY ADVANCES INTO COHORT 3 AS ENROLLMENT CONTINUES ENTERED THE THIRD AND FINAL DOSING COHORT OF THE AUSTRALIAN ONCOLOGY STUDY, EXPANDED THE HEMOPURIFIER INTELLECTUAL PROPERTY PORTFOLIO, AND MAINTAINED A FOCUS ON MANAGING OPERATING EXPENSES. CONFERENCE CALL TODAY AT 4:30 P.M.

AETHLON MEDICAL ANNOUNCES FISCAL YEAR END MARCH 31, 2026 FINANCIAL RESULTS AND CORPORATE UPDATE

SAN DIEGO, JUNE 2, 2026 /PRNEWSWIRE/ --AETHLON MEDICAL, INC. (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE THREATENING INFECTIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL ISSUE FINANCIAL RESULTS FOR ITS FISCAL YEAR END MARCH 31, 2026, AT 4:15 P.M. ET ON WEDNESDAY, JUNE 10, 2026.

AETHLON MEDICAL TO RELEASE FISCAL YEAR END FINANCIAL RESULTS AND HOST CONFERENCE CALL ON JUNE 10, 2026

SAN DIEGO, MAY 21, 2026 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE-THREATENING INFECTIOUS DISEASES, TODAY ANNOUNCED THAT IT IS ACTIVELY MONITORING DEVELOPMENTS RELATED TO THE CURRENT BUNDIBUGYO EBOLA VIRUS OUTBREAK IN DEMOCRATIC REPUBLIC OF THE CONGO AND UGANDA AND REMAINS PREPARED TO ENGAGE WITH GLOBAL HEALTHCARE AND REGULATORY AUTHORITIES REGARDING THE POTENTIAL INVESTIGATIONAL USE OF ITS HEMOPURIFIER TECHNOLOGY. ACCORDING TO RECENT REPORTS FROM THE WORLD HEALTH ORGANIZATION ("WHO") AND OTHER PUBLIC HEALTH AGENCIES, THE CURRENT OUTBREAK HAS BEEN IDENTIFIED AS INVOLVING THE BUNDIBUGYO STRAIN OF EBOLA VIRUS, A STRAIN FOR WHICH WE ARE NOT AWARE OF ANY APPROVED TREATMENTS BEYOND SUPPORTIVE CARE, AS OF THE DATE OF THIS RELEASE.

AETHLON MEDICAL MONITORING CURRENT EBOLA OUTBREAK AND REAFFIRMS OUTBREAK/PANDEMIC PREPAREDNESS

VANCOUVER, KELOWNA, AND DELTA, BRITISH COLUMBIA--(NEWSFILE CORP. - MARCH 24, 2026) - INVESTORIDEAS.COM, A GO-TO INVESTING PLATFORM, RELEASES AN INDUSTRY SNAPSHOT LOOKING AT ADVANCEMENTS IN NOVEL IMMUNOTHERAPEUTICS, FEATURING AETHLON MEDICAL, INC. (NASDAQ: AEMD), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING THE INVESTIGATIONAL AETHLON HEMOPURIFIER, AN EXTRACORPOREAL DEVICE FOR ONCOLOGY AND OTHER INDICATIONS. ADVANCEMENTS IN NOVEL IMMUNOTHERAPEUTICS IN THE ONCOLOGY BATTLE TO VIEW AN ENHANCED VERSION OF THIS GRAPHIC, PLEASE VISIT: HTTPS://IMAGES.NEWSFILECORP.COM/FILES/6292/289695_0E46DAB6145C8910_001FULL.JPG NOVEL IMMUNOTHERAPEUTICS HAVE TRANSFORMED ONCOLOGY, MOVING AWAY FROM BROAD, NON-SPECIFIC TREATMENTS TOWARD HIGHLY PERSONALIZED STRATEGIES THAT HARNESS THE PATIENT'S IMMUNE SYSTEM TO PRECISELY TARGET CANCER CELLS.

ADVANCEMENTS IN NOVEL IMMUNOTHERAPEUTICS IN THE ONCOLOGY BATTLE

SAN DIEGO, MARCH 24, 2026 /PRNEWSWIRE/ --AETHLON MEDICAL, INC. (NASDAQ: AEMD), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING THE INVESTIGATIONAL AETHLON HEMOPURIFIER, AN EXTRACORPOREAL DEVICE FOR ONCOLOGY AND OTHER INDICATIONS, TODAY ANNOUNCED THAT THE INDEPENDENT DATA SAFETY MONITORING BOARD (DSMB) OVERSEEING ITS ONGOING CLINICAL TRIAL AEMD-2022-06 HAS COMPLETED ITS SCHEDULED SAFETY REVIEW OF THE SECOND COHORT PARTICIPANT DATA AND RECOMMENDED ADVANCING TO THE THIRD AND FINAL COHORT. THEY ALSO STATED THAT "NO SAFETY CONCERNS WERE NOTED WITHHEMOPURIFIER DEVICE/PROCEDURE".

AETHLON MEDICAL, INC. ADVANCES TO FINAL COHORT IN ONCOLOGY CLINICAL TRIAL FOLLOWING POSITIVE DSMB REVIEW

SAN DIEGO, MARCH 12, 2026 /PRNEWSWIRE/ --AETHLON MEDICAL, INC. ("AETHLON" OR THE "COMPANY") (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE-THREATENING INFECTIOUS DISEASES, TODAY ANNOUNCED THAT IT IS EVALUATING A RANGE OF STRATEGIC OPPORTUNITIES AND HAS ENGAGED MAXIM GROUP LLC ("MAXIM") TO ACT AS THE COMPANY'S EXCLUSIVE FINANCIAL ADVISOR IN CONNECTION WITH THIS PROCESS. THE COMPANY ENGAGED MAXIM FOLLOWING PRELIMINARY INBOUND INTEREST REGARDING POTENTIAL STRATEGIC OPPORTUNITIES.

Aethlon Medical, Inc.

AEMD

Price

Financial Reports

No items found.

Press Releases

Aethlon Medical, Inc.

AEMD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

AEMD